Betting on cell memory, AbbVie pays Immunome $30M upfront to further antibody research
AbbVie has tapped Immunome’s discovery platform in a heavily backended partnership and option agreement in a bid to discover 10 antibody-target pairs from three as-yet-unnamed tumor types.
AbbVie will pay out $30 million upfront, but more could be on the way for Immunome, according to a joint press release.
As for more money, AbbVie could pay out up to $70 million in platform access payments for Immunome to continue research using its human memory B cell platform, Discovery Engine, as well as $120 million in development and commercial sale milestones for each antibody target “with respect to certain products derived” from the targets that AbbVie might want to buy – plus sales milestones of up to $150 million per target, which will be based on reaching certain levels of net sales of products, according to SEC filings.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.